Cargando…

Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil

This study used a prospectively managed clinical database in order to identify 1470 patients with gastrointestinal cancers receiving protracted venous infusion (PVI) fluorouracil (5FU). It aimed to determine the time course of toxicity due to PVI 5FU and to analyse factors predicting toxicity. The i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tebbutt, N C, Norman, A R, Cunningham, D, Allen, M, Chau, I, Oates, J, Hill, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377105/ https://www.ncbi.nlm.nih.gov/pubmed/12771914 http://dx.doi.org/10.1038/sj.bjc.6600917

Ejemplares similares

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
por: Saini, A, et al.
Publicado: (2003)

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan
por: Chong, G, et al.
Publicado: (2005)

Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
por: Chau, I, et al.
Publicado: (2001)

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
por: Sumpter, K, et al.
Publicado: (2005)

Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer
por: Chau, I, et al.
Publicado: (2003)

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
por: Rao, S, et al.
Publicado: (2004)

The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
por: Crawley, C., et al.
Publicado: (1998)

Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study
por: Ficorella, C, et al.
Publicado: (2004)

Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy
por: Chau, I, et al.
Publicado: (2004)

Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis
por: Damianovich, D, et al.
Publicado: (2007)

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
por: Maisey, N R, et al.
Publicado: (2005)

Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
por: Yamada, Y, et al.
Publicado: (2003)

A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site
por: Macdonald, A G, et al.
Publicado: (2002)

The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract
por: Formica, V, et al.
Publicado: (2007)

Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
por: Gusella, M, et al.
Publicado: (2009)

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer
por: Chao, Y, et al.
Publicado: (2004)

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract
por: Hsu, C, et al.
Publicado: (2004)

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
por: Rigg, A., et al.
Publicado: (1997)

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial
por: Waters, J S, et al.
Publicado: (1999)

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
por: Tebbutt, N C, et al.
Publicado: (2010)

Letter: Blood levels of 5-fluorouracil during intravenous infusion.
por: Kawai, M., et al.
Publicado: (1976)

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer
por: Borro, Marina, et al.
Publicado: (2016)

Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2002)

Unpredicted Severe Toxicity after 5-Fluorouracil Treatment due to Dihydropyrimidine Dehydrogenase Deficiency
por: Baek, Jin Ho, et al.
Publicado: (2006)

Effects of the Plasma Concentration of 5‐Fluorouracil and the Duration of Continuous Venous Infusion of 5‐Fluorouracil with an Inhibitor of 5‐Fluorouracil Degradation on Yoshida Sarcomas in Rats
por: Fujii, Setsuro, et al.
Publicado: (1989)

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study
por: Humphreys, A C, et al.
Publicado: (2004)

Pharmacokinetic Modulation of Plasma 5‐Fluorouracil Concentrations to Potentiate the Antitumor Activity of Continuous Venous Infusion of 5‐Fluorouracil
por: Fujii, Setsuro, et al.
Publicado: (1989)

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
por: Milano, G, et al.
Publicado: (1999)

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
por: Rao, S, et al.
Publicado: (2005)

Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution.
por: Kerr, D. J., et al.
Publicado: (1996)

High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma.
por: Highley, M. S., et al.
Publicado: (1993)

Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer: A phase II study
por: Gural, Zeynep, et al.
Publicado: (2018)

Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
por: Bamias, A., et al.
Publicado: (1995)

Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
por: Yeh, K H, et al.
Publicado: (2005)

In vivo cell synchrony in the L1210 mouse leukaemia studied with 5-fluorouracil or 5-fluorouracil followed by cold thymidine infusion.
por: Camplejohn, R. S., et al.
Publicado: (1977)

Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin
por: Gonzalez, M A, et al.
Publicado: (2003)

Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut
por: Bach, S P, et al.
Publicado: (2006)

The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
por: Goldberg, J. A., et al.
Publicado: (1990)

Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
por: Cho, Eun Kyung, et al.
Publicado: (2002)

Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma
por: Gao, Jian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0td9jsd7f13n1t5jna60jpvrll